Search alternatives:
a decrease » _ decreased (Expand Search), _ decreases (Expand Search)
w decrease » we decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 w » 5 wt (Expand Search)
Showing 1 - 20 results of 80,376 for search '(( 19 _ decrease ) OR ((( 5 ((a decrease) OR (mean decrease)) ) OR ( 5 w decrease ))))', query time: 1.00s Refine Results
  1. 1
    MMP-2 production is decreased following ALK5 inhibition.

    MMP-2 production is decreased following ALK5 inhibition. by Rebecca A. Scott (488956)

    Published 2020
    Save to List
    Saved in:
  2. 2
    LuxR G37V has decreased DNA-binding activity.

    LuxR G37V has decreased DNA-binding activity. by Chelsea A. Simpson (9579303)

    Published 2024
    Save to List
    Saved in:
  3. 3
    Effects of SNPs on the Protein Stability, Increasing or Decreasing.

    Effects of SNPs on the Protein Stability, Increasing or Decreasing. by Mirza Jawad Ul Hasnain (8351388)

    Published 2020
    Save to List
    Saved in:
  4. 4
    Deletion of <i>sagA</i> alone results in a decrease in nasopharyngeal infection.

    Deletion of <i>sagA</i> alone results in a decrease in nasopharyngeal infection. by Blake A. Shannon (14197601)

    Published 2024
    Save to List
    Saved in:
  5. 5
    Inhibition of ABCG2 decreases SP cells, but not sphere-forming ability.

    Inhibition of ABCG2 decreases SP cells, but not sphere-forming ability. by Noriko Kawai (6694010)

    Published 2019
    Save to List
    Saved in:
  6. 6
    Variable importance plot (mean decrease accuracy and mean decrease Gini).

    Variable importance plot (mean decrease accuracy and mean decrease Gini). by Fernando Martinez-Taboada (8655132)

    Published 2020
    Save to List
    Saved in:
  7. 7
    Maximum IFN concentrations are decreased in severe patients.

    Maximum IFN concentrations are decreased in severe patients. by Sonia T. Gazeau (21512764)

    Published 2025
    Save to List
    Saved in:
  8. 8
    Hypothesis that explains and predicts expansion of ages of KD due to decreased IgG levels.

    Hypothesis that explains and predicts expansion of ages of KD due to decreased IgG levels. by Hiromi Yamaguchi (2396248)

    Published 2022
    Subjects:
    Save to List
    Saved in:
  9. 9
    Baseline patient characteristics across neutralizing monoclonal antibody trials.

    Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  10. 10
    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies.

    Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  11. 11
    Study Flow Diagram.

    Study Flow Diagram. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  12. 12
    Antibody and antigen responses to Ensovibep vs placebo day 1–90.

    Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  13. 13
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  14. 14
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  15. 15
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  16. 16
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  17. 17
    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90.

    Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  18. 18
    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab.

    Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  19. 19
    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis).

    Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  20. 20
    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity.

    Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

    Published 2025
    Subjects:
    Save to List
    Saved in:

Search Tools: